Sergei V Kotenko

20090220511, Sep 3, 2009

Feb 10, 2003

10/503866

Sergei Kotenko - East Brunswick NJ, US
Grant Gallagher - East Brunswick NJ, US

A61K 39/395
C07H 21/04
C12N 15/63
C12N 5/00
C07K 14/435
C07K 16/00
G01N 33/53
C12Q 1/68

4241391, 536 231, 4353201, 435325, 530350, 5303879, 435 71, 435 6

A novel IFN-α/β independent ligand receptor system which upon engagement leads, among other things, to the establishment of an anti-viral state is disclosed. Further disclosed are three closely positioned genes on human chromosome 19 that encode distinct but highly homologous proteins, designated IFN-λ1, IFN-λ2, IFN-λ3, based, inter alia, in their ability to induce antiviral protection. Expression of these proteins is induced upon viral infection. A receptor complex utilized by all three IFN-λ proteins for signaling is also disclosed. The receptor complex is generally composed of two subunits, a novel receptor designated IFN-λR1 or CRF2-12, and a second subunit, IL-10R2 or CRF2-4, which is also a shared receptor component for the IL-10 and IL-22 receptor complexes. The gene encoding IFN-λR1 is generally widely expressed, including many different cell types and tissues. Expression of these proteins is induced by immune events, including, for example, upon viral infection. Apoptotosis may also be induced under effective conditions.

20110027282, Feb 3, 2011

Aug 23, 2007

12/310432

Sergei V. Kotenko - East Brunswick NJ, US
Geoffrey L. Smith - Oxon, GB

A61K 39/395
A61K 38/16
C07H 21/00
C07K 14/065
C12N 15/63
C12N 5/10
C12N 1/00
C07K 16/10
C40B 30/04
C07H 21/02
A61P 37/02
A61P 37/06
A61P 31/12
A61P 31/00

4241391, 514 212, 536 234, 530350, 4353201, 435325, 435243, 514 14, 514 37, 5303879, 5303873, 506 9, 536 245

Described are compositions and methods useful for modulating the immune system of a subject. Also included are diagnostic methods for monitoring an immunologic condition. In particular the invention relates to antagonists of interferon proteins and associated methods of use as well as methods to develop neutralizing antibodies against IFN antagonists to treat viral infections.

20110038854, Feb 17, 2011

Mar 30, 2007

12/295619

Sergei V. Kotenko - East Brunswick NJ, US

University of Medicine and Dentistry of New Jersey - Somerset NJ

A61K 39/395
C07K 14/00
C12N 5/10
C07H 21/00
A61K 38/16
C12N 15/63
C07K 16/00
C12N 5/071
A61P 43/00

4241331, 530350, 435325, 536 231, 514 212, 4353201, 5303873

The present invention describes a chimeric polypeptide comprising a first portion comprising a receptor domain, wherein the receptor domain comprises an intracellular region and a transmembrane region; and a second portion comprising a dimerization domain. The present invention also describes a chimeric polypeptide comprising a first portion comprising a receptor domain, wherein the receptor domain comprises a receptor extracellular region; and a second portion comprising a dimerization domain, wherein the dimerization domain comprises an antibody heavy chain region of a Fab fragment or an antibody light chain region. Polynucleotides encoding the chimeric polypeptides and methods of use of the chimeric polypeptides are also described.

20110171173, Jul 14, 2011

Oct 5, 2010

12/898320

Sergei Kotenko - East Brunswick NJ, US
Grant F. Gallagher - Milltown NJ, US

UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY - Somerset NJ

A61K 38/21
C07H 21/00
C12N 15/63
C12N 1/00
C12N 5/10
C07K 14/555
C07K 16/24
C07K 16/28
A61K 39/395
G01N 33/53
C12Q 1/68
A61P 37/04

424 854, 536 235, 536 234, 536 232, 4353201, 536 2352, 435243, 435325, 435419, 530351, 530324, 5303879, 4241581, 5303892, 436501, 435 61

A novel IFN-α/β independent ligand receptor system which upon engagement leads, among other things, to the establishment of an anti-viral state is disclosed. Further disclosed are three closely positioned genes on human chromosome 19 that encode distinct but highly homologous proteins, designated IFN-λ1, IFN-λ2, IFN-λ3, based, inter alia, in their ability to induce antiviral protection. Expression of these proteins is induced upon viral infection. A receptor complex utilized by all three IFN-λ proteins for signaling is also disclosed. The receptor complex is generally composed of two subunits, a novel receptor designated IFN-λR1 or CRF2-12, and a second subunit, IL-10R2 or CRF2-4, which is also a shared receptor component for the IL-10 and IL-22 receptor complexes. The gene encoding IFN-λR1 is generally widely expressed, including many different cell types and tissues. Expression of these proteins is induced by immune events, including, for example, upon viral infection. Apoptotosis may also be induced under effective conditions.

20120114603, May 10, 2012

Oct 5, 2010

12/898141

Sergei Kotenko - East Brunswick NJ, US
Grant F. Gallagher - Milltown NJ, US

UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY - Somerset NJ

A61K 38/21
G01N 33/567
C07H 21/04
G01N 33/566
C07K 14/57
C07K 16/24
A61K 39/395
C12N 5/10

424 855, 4241391, 435 721, 435352, 435358, 436501, 530351, 5303879, 536 2352

A novel IFN-α/β independent ligand receptor system which upon engagement leads, among other things, to the establishment of an anti-viral state is disclosed. Further disclosed are three closely positioned genes on human chromosome 19 that encode distinct but highly homologous proteins, designated IFN-λ1, IFN-λ2, IFN-λ3, based, inter alia, in their ability to induce antiviral protection. Expression of these proteins is induced upon viral infection. A receptor complex utilized by all three IFN-λ proteins for signaling is also disclosed. The receptor complex is generally composed of two subunits, a novel receptor designated IFN-λR1 or CRF2-12, and a second subunit, IL-10R2 or CRF2-4, which is also a shared receptor component for the IL-10 and IL-22 receptor complexes. The gene encoding IFN-λR1 is generally widely expressed, including many different cell types and tissues. Expression of these proteins is induced by immune events, including, for example, upon viral infection. Apoptotosis may also be induced under effective conditions.